These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33466182)

  • 1. The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis.
    He X; Zhang T; Wu L; Wu Y; Zhou X
    Medicine (Baltimore); 2021 Jan; 100(2):e24110. PubMed ID: 33466182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
    Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
    Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
    Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
    Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
    Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer.
    Zhou K; Zhou J; Zhang M; Liao W; Li Q
    Clin Transl Oncol; 2020 Mar; 22(3):337-343. PubMed ID: 31041716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trifluridine/tipiracil in the treatment of gastric cancer.
    Fostea RM; Arkenau HT
    Future Oncol; 2022 Apr; 18(12):1511-1517. PubMed ID: 35081748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trifluridine/tipiracil for the treatment of metastatic gastric cancer.
    Kawazoe A; Shitara K
    Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):65-70. PubMed ID: 31920125
    [No Abstract]   [Full Text] [Related]  

  • 9. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
    Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
    Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
    Zaniboni A; Barone CA; Banzi MC; Bergamo F; Blasi L; Bordonaro R; Bartolomeo MD; Costanzo FD; Frassineti GL; Garufi C; Giuliani F; Latiano TP; Martinelli E; Personeni N; Racca P; Tamburini E; Tonini G; Besse MG; Spione M; Falcone A
    Future Oncol; 2021 Jun; 17(18):2315-2324. PubMed ID: 33663264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
    Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
    Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
    Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E
    Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
    Giuliani J; Bonetti A
    Eur J Cancer; 2020 Oct; 138():77-79. PubMed ID: 32871525
    [No Abstract]   [Full Text] [Related]  

  • 15. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
    Hamada S; Komatsu S; Shibata R; Konishi T; Matsubara D; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2056-2058. PubMed ID: 33468799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
    Narita Y; Shoji H; Kawai S; Mizukami T; Nakamura M; Moriwaki T; Yamanaka T; Sunakawa Y; Kawakami H; Nishina T; Misumi T; Muro K
    Future Oncol; 2021 Mar; 17(8):869-875. PubMed ID: 32954810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
    Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
    Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers.
    Hamerton L; Gomes K; Fougeray R; Hook ES; Gomes MV; Hauch O; Bullement A
    Future Oncol; 2023 Mar; 19(9):643-650. PubMed ID: 37115022
    [No Abstract]   [Full Text] [Related]  

  • 20. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.